Lili Yang PhD

Lili Yang, PhD, received her PhD in Biology from the California Institute of Technology (Caltech), studying with David Baltimore, PhD. She is currently Professor of Microbiology, Immunology and Molecular Genetics at UCLA. Her research laboratory at UCLA studies tumor immunology and cancer immunotherapy, with a special focus on developing gene and cell- based immunotherapy for cancer (https://www. liliyanglab.com/). So far her work has resulted in over 70 publications, 27 patents, two clinical trials and two biotech startups.

In recognition of her scientific achievements, Dr. Yang has received multiple prestigious awards, including a TR35 (Innovators Under 35) Award from the MIT Technology Review Magazine, a Director’s New Innovator Award from the National Institute of Health (NIH), a Young Investigator Award from the American Association of Immunologists (AAI), and an Outstanding New Investigator Award from the American Society of Gene & Cell Therapy (ASGCT).

Dr. Yang is also widely recognized for her biotech accomplishments. She has been named to the Women in Biopharma list by Endpoints News in 2022 and Top Women in Academic Entrepreneurship by BIOS in 2023.

• TR35 (Innovators Under 35) Award, MIT Technology Review Magazine
• Director’s New Innovator Award, National Institute of Health (NIH)
• Young Investigator Award, American Association of Immunologists (AAI)
• Outstanding New Investigator Award, American Society of Gene & Cell Therapy (ASGCT)
• Women in Biopharma, Endpoints News (2022)
• Top Women in Academic Entrepreneurship, BIOS (2023)